As a tumor suppressor, the loss of FAT1 promotes resistance to CDK4/6 inhibitors via the Hippo pathway (Li et al., 2018), which was expressed at low levels in the high-risk group among patients with HER2− BC. Here, ERBB2 is linked to breast cancer.